Home Featured Page 70

Featured

Latest

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Pα+ Psychedelic Patent Analysis: April 2024

Breaking Through Bureaucracy: Can D.C. Embrace Evidence-Based Drug Policy?

Pα+ Psychedelic Bulletin #163: Tempering Excitement Around Recent Raises; Compass Shares...

Depth Psychology, Archetypal Energies, and How Psychedelics Reveal the Soul

California’s Latest Psychedelics Bill Dies in Committee

Examining the Inner Healer Approach to Psychedelic Therapy

“We’re Going to See Demand for This Go Through the Roof”:...

Third Wave – Navigating Psychedelic Business Realities: Insights & Lessons

True Life Podcast – Take a DEEP Breath… It’s VITAL

The High Guide – Unlocking the Potential: Psychedelic Workforce Insights with...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Pα+ Psychedelic Patent Analysis: April 2024

Breaking Through Bureaucracy: Can D.C. Embrace Evidence-Based Drug Policy?

Pα+ Psychedelic Bulletin #163: Tempering Excitement Around Recent Raises; Compass Shares...

Depth Psychology, Archetypal Energies, and How Psychedelics Reveal the Soul

California’s Latest Psychedelics Bill Dies in Committee

Examining the Inner Healer Approach to Psychedelic Therapy

“We’re Going to See Demand for This Go Through the Roof”:...

Third Wave – Navigating Psychedelic Business Realities: Insights & Lessons

True Life Podcast – Take a DEEP Breath… It’s VITAL

The High Guide – Unlocking the Potential: Psychedelic Workforce Insights with...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY